Introduction
============

Glomerulus nephritis (GN) is an autoimmune system disease with complex pathogenesis, diverse pathological classifications and long disease course ([@b1-etm-0-0-8824]). It can be induced by various causes and can be divided into primary glomerulonephritis (PGN) and secondary glomerulonephritis (SGN) ([@b2-etm-0-0-8824]). The pathogenic process of GN is divided into several stages: first edema, hematuria or proteinuria can be seen in the body; then, renal function weakens; eventually, patients suffer renal failure ([@b3-etm-0-0-8824]). At present, the drugs used to treat GN in clinic are few, and the efficacy of some drugs is poor, causing adverse reactions. Moreover, the treatment is expensive ([@b4-etm-0-0-8824]). Comprehensive preventive measures should be taken in the treatment of GN to control deterioration of renal function, alleviate the symptoms of patients, reduce the incidence of serious complications and improve patients\' life quality ([@b5-etm-0-0-8824]).

Serum cystatin C (C\'s C) is a non-glycosylated small protein, with 120 amino acid residues, and is a member of cysteine protease inhibitors ([@b6-etm-0-0-8824]). The production rate of C\'s C is relatively constant in body fluids and nucleated cells in tissues of the body. C\'s C metabolizes and regulates peptides and proteins in cells ([@b7-etm-0-0-8824]). In the blood circulation of the body, C\'s C is filtered by glomerular filtration membrane and is reabsorbed by proximal convoluted tubules. The glomerular filtration function directly determines the level of C\'s C in the serum ([@b8-etm-0-0-8824],[@b9-etm-0-0-8824]).

Vascular endothelial growth factor (VEGF), a dynamic source of division and growth of endothelial cells, facilitates angiogenesis. VEGF can combine with soluble vascular endothelial growth factor receptor 1 (sVEGFR1) to prevent VEGF membrane receptors from mediating and taking a biological effect. sVEGFR1 and VEGF membrane receptors are competitive, when they are combined with VEGF, the biological activity of sVEGFR1 and VEGF will be regulated negatively ([@b10-etm-0-0-8824],[@b11-etm-0-0-8824]). Studies have shown that when sVEGFR1 combines with VEGF in the blood circulation, the function of VEGF will be regulated. Increasing the level of sVEGFR1 prevents VEGF from facilitating angiogenesis and injuring endothelial cells, which is closely related to kidney diseases ([@b12-etm-0-0-8824]).

Studies on the expression of serum C\'s C and sVEGFR1 in patients with GN and predictive function and evaluation function of serum C\'s C and sVEGFR1 in diseases are scarce. Therefore, expression levels of serum C\'s C and sVEGFR1 in the treatment of patients with GN were detected and the monitoring function and significance of serum C\'s C and sVEGFR1 in GN were investigated in this study, in order to provide specific study data and theoretical basis for clinical treatment of GN.

Patients and methods
====================

### General data

The medical records of 88 patients with GN who were diagnosed in Weifang People\'s Hospital (Weifang, China) from March 2014 to June 2017 were collected, and their medical records were considered as study group. The study group was divided to SGN group and PGN group. There were 52 patients in SGN group and 36 patients in PGN group. Physical examination data of 50 healthy volunteers who were examined in Weifang People\'s Hospital during the same period were considered as the control group. Among those patients, there were 66 males and 72 females, with an average age of 45.0±15.7 years and a BMI of 21.0±3.6. There was no significant difference in some data of the patients in two groups, including gender, age and BMI (P\>0.05). There were significant differences in hypertension, edema and some other aspects (P\<0.05) ([Table I](#tI-etm-0-0-8824){ref-type="table"}).

### Inclusion and exclusion criteria

Inclusion criteria: Patients who were diagnosed with GN by histopathology were included; Serum creatinine (SCr) \<350 mol/l, and blood urea nitrogen (BUN) \<17 mmol/l; urine RBC was increased and showed tubular shape ([@b13-etm-0-0-8824]).

Exclusion criteria: i) patients with malignant tumors; ii) patients complicated with solid lesions of other organs; iii) patients complicated with blood diseases and infection; iv) patients with cognitive disorder or communication disorder; v) patients with poor compliance.

All the patients and their family members agreed to participate in the experiment, and an informed consent form was signed. This experiment was approved by the Medical Ethics Committee of Weifang People\'s Hospital.

### Reagents and materials

The serum separation centrifuge was purchased from Zhengzhou Zhishi Changyun Technology Co., Ltd. C\'s C was was detected by automatic biochemical analyzer BS-600 (Shenzhen Mindray Biomedical Electronics Co., Ltd.); C\'s C test kits (Shenzhen ziker Biological Technology Co., Ltd., ZK-H068); sVEGFR1 kits were from R&D Systems (ML-ELISA-0073).

### Experiment methods

The patients were treated for more than 3 cycles. The specific therapeutic regimen was as follows: the patients took valsartan dispersible tablets once a day, and the dosage was 80 mg per time. Alprostadil injection (10 µg) was mixed with sodium chloride solution with a concentration of 0.9%, then the patients were injected with the mixture once a day, the dosage was 100 ml per time. Fasting venous blood (5 ml) of the patients and the healthy volunteers was collected in the morning, then the serum was separated from the blood by serum separation centrifuge at a speed of 1,500 x g at 4˚C for 10 min, and the serum was reserved. Serum C\'s C of the patients was detected by immunoturbidimetry. The expression level of sVEGFR1 in the serum was detected by enzyme-linked immunosorbent assay (ELISA). The procedures were carried out strictly according to the instructions of the kits.

### Observation indicators

i\) The expression levels of C\'s C and sVEGFR1 in serum of the patients in the study group and the control group were compared before treatment. ii) The changes of expression levels of serum C\'s C of the patients in PGN group and SGN group were compared before they were treated, after one cycle of treatment, after three cycles of treatment and after discharged from the hospital. iii) The changes of expression levels of sVEGFR1 of the patients in PGN group and SGN group were compared before they were treated, after one cycle of treatment, after three cycles of treatment and after discharged from the hospital. iv) The correlation between the expression of C\'s C and the expression of sVEGFR1 in GN was analyzed by correlation analysis.

### Statistical analysis

In this study, SPSS 19.0 (Bizinsight (Beijing) Information Technology Co., Ltd.) was used to statistically analyze the experimental data. The count data were analyzed by χ^2^ test. The measurement data were expressed in the form of mean value ± standard deviation. t-test was used in comparison of data between two groups. Bonferroni test was the post hoc test. Repeated measures analysis of variance was used in comparison of the data between two groups at different time points in the treatment of patients. Pearson analysis was used to carry out correlation analysis of the data. The illustrations of this experiment were drawn by GraphPad Prism 8. P\<0.05 indicates statistically significant difference.

Results
=======

### Comparison of expression levels of C\'s C and sVEGFR1 of the patients in the study and the control groups

The expression levels of C\'s C and sVEGFR1 of the patients in the study group and the subjects in the control group were compared before treatment. The expression level of C\'s C of the patients in the study group was significantly higher than that in control group. The expression level of sVEGFR1 of the patients in study group was significantly higher than that in the control group. Differences in expression levels of C\'s C and sVEGFR1 of the patients in the two groups were statistically significant (P\<0.05) ([Table II](#tII-etm-0-0-8824){ref-type="table"}).

### Comparison of the changes of expression level of C\'s C of the patients in PGN and SGN groups before treatment, one cycle after treatment, three cycles after treatment and after discharge

The expression level of C\'s C of the patients in PGN group and SGN group was compared before treatment, after one cycle of treatment, after three cycles of treatment, and after discharge from hospital. It was found that the expression level of C\'s C of the patients in PGN group and SGN group decreased gradually after one cycle of treatment. The expression level of C\'s C of the patients in PGN group and SGN group after one cycle of treatment was lower than that before they were treated (P\<0.05). The expression level of C\'s C of the patients in PGN group and SGN group decreased gradually after three cycles of treatment. The expression level of C\'s C of the patients in PGN group and SGN group after three cycles of treatment was lower than that after one cycle of treatment (P\<0.05). The expression level of C\'s C of the patients in PGN group and SGN group decreased gradually after discharge from hospital. The expression level of C\'s C of the patients in PGN group and SGN group after discharged from the hospital was lower than that after three cycles of treatment (P\<0.05). There was no significant difference between the expression level of C\'s C of the patients in PGN group and that in SGN group (P\>0.05) ([Table III](#tIII-etm-0-0-8824){ref-type="table"} and [Fig. 1](#f1-etm-0-0-8824){ref-type="fig"}).

### Comparison of the changes of expression level of sVEGFR1 of the patients in PGN and SGN groups before treatment, one cycle after treatment, in three cycles after treatment and after discharge

The expression level of sVEGFR1 of the patients in PGN group and SGN group was compared before they were treated, after a cycle of treatment, after three cycles of treatment, and after they discharged from the hospital. It was found that the expression level of sVEGFR1 of the patients in PGN group and SGN group decreased gradually after a cycle of treatment. The expression level of sVEGFR1 of the patients in PGN group and SGN group after a cycle of treatment was lower than that before they were treated (P\<0.05). The expression level of sVEGFR1 of the patients in PGN group and SGN group decreased gradually after three cycles of treatment. The expression level of sVEGFR1 of the patients in PGN group and SGN group after three cycles of treatment was lower than that after one cycle of treatment (P\<0.05). The expression level of sVEGFR1 of the patients in PGN group and SGN group decreased gradually after discharge from the hospital. The expression level of sVEGFR1 of the patients in PGN group and SGN group after discharge from hospital was lower than that after three cycles of treatment (P\<0.05). There was no significant difference between the expression level of sVEGFR1 of the patients in PGN group and that in SGN group (P\>0.05) ([Table IV](#tIV-etm-0-0-8824){ref-type="table"} and [Fig. 2](#f2-etm-0-0-8824){ref-type="fig"}).

### Changes in renal function in different periods of treatment

The results showed that with the increase of the treatment cycle, the renal function indexes of patients in the study group showed a downward trend (P\<0.05) ([Table V](#tV-etm-0-0-8824){ref-type="table"}).

### Correlation analysis of expression of C\'s C and sVEGFR1 in GN and the renal function indexes

According to Spearman\'s correlation analysis, the expression of C\'s C and sVEGFR1 was positively correlated in GN (r=0.740, P\<0.001). Due to the positive correlation between the expression of C\'s C and sVEGFR1, the association between the expression of C\'s C and urea nitrogen, creatinine were analyzed. Spearman\'s correlation results showed that C\'s C expression was positively correlated with urea nitrogen (r=0.797, P\<0.001), and C\'s C expression was positively correlated with creatinine (r=0.841, P\<0.001) ([Fig. 3](#f3-etm-0-0-8824){ref-type="fig"}).

Discussion
==========

At present, it is believed that GN can lead to end-stage renal diseases and its pathological changes are complex. For many GN diseases, cellular immunity plays a decisive role, and humoral immunity is also clearly expressed during the pathogenic process of GN diseases ([@b14-etm-0-0-8824]). In addition, the disorder of blood coagulation mechanism and the change of blood rheology have an effect on the occurrence and progression of glomerular diseases ([@b15-etm-0-0-8824]). In clinic, the pathogenesis and treatment of GN are known, the drugs used to treat GN are immunosuppressive agents and glucocorticoid, but the efficacy of many glomerular diseases is still unsatisfactory ([@b16-etm-0-0-8824],[@b17-etm-0-0-8824]). In order to evaluate the changes of patients\' condition in the occurrence and progression of GN disease and improve clinical symptoms of the patients, and the cure rate, the expression of C\'s C and sVEGFR1 in GN was investigated. C\'s C is an independent endogenous marker, only filtered and metabolized by kidneys. C\'s C is important in the early diagnosis of renal injury and is highly recognized for evaluating glomerular function in clinic ([@b18-etm-0-0-8824],[@b19-etm-0-0-8824]). sVEGFR1 is produced in endothelial cells, monocytes and placenta. As a soluble receptor of VEGF, it negatively regulates the activity of VEGF ([@b20-etm-0-0-8824]). When sVEGFR1 is combined with VEGF, the signal transduction acts on angiogenesis, when this process is disrupted, a series of pathological conditions will occur, such as the deterioration of renal function, which is caused by injury of vascular endothelial cell function ([@b21-etm-0-0-8824]).

In this study, the expression levels of C\'s C and sVEGFR1 of the patients in the study group and the control group were compared. It was found that the expression levels of C\'s C and sVEGFR1 of the patients in the study group were significantly higher than those in the control group. The results indicated that the expression levels of C\'s C and sVEGFR1 were diagnostic markers in the occurrence and progression of glomerular nephropathy. Some studies reported that the occurrence and progression of GN diseases are related to cellular immunity, serum free radicals, and coagulation mechanism, and that the occurrence and development of GN diseases are closely related to cellular immunity ([@b22-etm-0-0-8824]). C\'s C is a cysteine protease inhibitor that can be used to detect the filtration rate of glomeruli in kidney injury. The practical method to detect C\'s C is immunoassay ([@b23-etm-0-0-8824]). The signal transduction of sVEGFR1 improves hematopoietic function, proliferative function, differentiation function and immune function of monocytes and macrophages of hematopoietic stem cells (HSC) ([@b24-etm-0-0-8824]). The changes of cellular immunity exist in the expression of C\'s C and sVEGFR1, which indirectly confirms the conclusion of this study. To investigate the specific changes of the expression levels of C\'s C and sVEGFR1 in GN, the changes of expression levels of C\'s C and sVEGFR1 were investigated before and after treatment of patients. The results showed that expression levels of serum C\'s C and sVEGFR1 of the patients in PGN group and SGN group decreased gradually after a cycle of treatment. Expression levels of serum C\'s C and sVEGFR1 of the patients in PGN group and SGN group after a cycle of treatment were lower than those before treatment (P\<0.05). Expression levels of serum C\'s C and sVEGFR1 of the patients in PGN group and SGN group decreased gradually after three cycles of treatment. Expression levels of serum C\'s C and sVEGFR1 of the patients in PGN group and SGN group after three cycles of treatment were lower than those after a cycle of treatment (P\<0.05). Expression levels of serum C\'s C and sVEGFR1 of the patients in PGN group and SGN group decreased gradually after they discharged. Expression levels of serum C\'s C and sVEGFR1 of the patients in PGN group and SGN group after discharged from hospital were lower than those after three cycles of treatment (P\<0.05). Previous studies have shown that the pathogenesis of secondary glomerular diseases and primary glomerular diseases is completely different, while their clinical manifestations and pathological changes are similar ([@b25-etm-0-0-8824]). Previous studies have demonstrated that C\'s C can be expressed effectively in the occurrence and progression of kidney diseases. With the deterioration of pathological conditions, the filtration rate of glomeruli decreases and the expression level of C\'s C increases ([@b26-etm-0-0-8824]). When the glomerular filtration barrier is injured and the repair of endothelial cells is blocked, the biological effects of VEGF will be inhibited and respond to the expression of sVEGFR1 negatively ([@b27-etm-0-0-8824]). In this study, the changes of expression of C\'s C and sVEGFR1 were investigated before and after treatment. The result showed that the expression levels of C\'s C and sVEGFR1 decreased with the continuous treatment of the patients. This result indicates that the expression of C\'s C and sVEGFR1 can be used as an indicator for monitoring the condition of patients with GN when they are treated. The correlation between expression of C\'s C and expression of sVEGFR1 was analyzed. The result showed that the expression of C\'s C and sVEGFR1 was positively correlated in GN. This result suggests that C\'s C and sVEGFR1 are associated with the progression of GN. Some studies ([@b28-etm-0-0-8824]) demonstrated that endogenous creatinine clearance was an important indicator to evaluate the filtration rate of glomeruli. Endogenous creatinine clearance and expression of C\'s C are related to the pathogenic process of GN. At present, studies on sVEGFR1 and the correlation between C\'s C and sVEGFR1 are few, so the specific mechanism of C\'s C and sVEGFR1 needs further investigation.

In conclusion, C\'s C and sVEGFR1 are highly expressed in serum of GN patients. As patients are treated, the expression levels of C\'s C and sVEGFR1 decrease. C\'s C and sVEGFR1 play important roles in monitoring the condition of GN patients during treatment.
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![Comparison of the expression level of C\'s C of the patients in PGN group and SGN group before treatment, in one cycle after treatment, in three cycles after treatment and after they were discharged from hospital. The result of immunoturbidimetry showed that the expression level of C\'s C of the patients in PGN group and SGN group decreased gradually in one cycle after treatment. The expression level of C\'s C of the patients in PGN group and SGN group one cycle after treatment was lower than that before treatment (P\<0.05). Expression level of C\'s C of the patients in PGN group and SGN group decreased gradually in three cycles after treatment. Expression level of C\'s C of the patients in PGN group and SGN group in three cycles after treatment was lower than that in one cycle after treatment (P\<0.05). Expression level of C\'s C of the patients in PGN group and SGN group decreased gradually after they were discharged from hospital. Expression level of C\'s C of the patients in PGN group and SGN group after discharge was lower than that in three cycles after they were treated (P\<0.05). There was no significant difference between the expression level of C\'s C of the patients in PGN group and that in SGN group (P\>0.05). ^\*^P\<0.05. C\'s C, serum cystatin C; PGN, primary glomerulonephritis; SGN, secondary glomerulonephritis.](etm-20-02-1550-g00){#f1-etm-0-0-8824}

![Comparison of the expression level of sVEGFR1 of the patients in PGN group and SGN group before treatment, in one cycle after treatment, in three cycles after treatment and after they were discharged from hospital. The result of ELISA showed that the expression level of sVEGFR1 of the patients in PGN group and SGN group decreased gradually in one cycle after treatment. Expression level of sVEGFR1 of the patients in PGN group and SGN group one cycle after treatment was lower than that before treatment (P\<0.05). Expression level of sVEGFR1 of the patients in PGN group and SGN group decreased gradually in three cycles after treatment. Expression level of sVEGFR1 of the patients in PGN group and SGN group in three cycles after they were treated was lower than that in one cycle after they were treated (P\<0.05). Expression level of sVEGFR1 of the patients in PGN group and SGN group decreased gradually after discharge from hospital. Expression level of sVEGFR1 of the patients in PGN group and SGN group after discharge was lower than that in three cycles after they were treated (P\<0.05). There was no significant difference between the expression level of sVEGFR1 of the patients in PGN group and that in SGN group (P\>0.05). ^\*^P\<0.05. sVEGFR1, soluble vascular endothelial growth factor receptor 1; PGN, primary glomerulonephritis; SGN, secondary glomerulonephritis.](etm-20-02-1550-g01){#f2-etm-0-0-8824}

![Correlation analysis of expression of C\'s C and sVEGFR1 in GN, the renal function indexes. (A) According to Spearman\'s correlation analysis, the expression of C\'s C and sVEGFR1 was positively correlated in GN (r=0.740, P\<0.001). (B) C\'s C expression was positively correlated with urea nitrogen (r=0.797, P\<0.001). (C) C\'s C expression was positively correlated with creatinine (r=0.841, P\<0.001). C\'s C, serum cystatin C; sVEGFR1, soluble vascular endothelial growth factor receptor 1; GN, glomerulus nephritis; PGN, primary glomerulonephritis; SGN, secondary glomerulonephritis.](etm-20-02-1550-g02){#f3-etm-0-0-8824}

###### 

General data of the patients in the study group and the control group \[n (%)\].

  Factors                  Study group (n=88)   Control group (n=50)   χ^2^/t   P-value
  ------------------------ -------------------- ---------------------- -------- ---------
  Sex                                                                  0.105    0.746
       Male                43 (48.86)           23 (46.00)                       
       Female              45 (51.14)           27 (54.00)                       
  Age (years)                                                          0.001    0.975
       ≤45                 46 (52.27)           26 (52.00)                       
       \>45                42 (47.73)           24 (48.00)                       
  BMI (kg/m^2^)                                                        0.178    0.673
       ≤21                 42 (47.73)           22 (44.00)                       
       \>21                46 (52.27)           28 (56.00)                       
  Hypertension                                                         48.391   \<0.001
       Yes                 63 (71.59)           5 (10.00)                        
       No                  25 (28.41)           45 (90.00)                       
  Edema                                                                63.971   \<0.001
       Yes                 62 (70.45)           0                                
       No                  26 (29.55)           50 (100.00)                      
  Hematuresis                                                          60.311   \<0.001
       Yes                 60 (68.18)           0                                
       No                  28 (31.82)           50 (100.00)                      
  Proteinuria                                                          76.171   \<0.001
       Yes                 68 (77.27)           0                                
       No                  20 (22.73)           50 (100.00)                      
  Urea nitrogen (mmol/l)   14.34±1.23           5.65±0.83              44.500   \<0.001
  Creatinine (µmol/l)      293.43±32.32         81.34±11.25            44.820   \<0.001

###### 

Comparison of expression levels of C\'s C and sVEGFR1 in the two groups.

  Groups           Study group (n=88)   Control group (n=50)   t        P-value
  ---------------- -------------------- ---------------------- -------- ---------
  C\'sC (mg/l)     2.43±0.45            0.83±0.18              24.040   \<0.001
  sVEGFR1 (µg/l)   30.42±7.42           7.34±1.54              21.700   \<0.001

C\'s C, serum cystatin C; sVEGFR1, soluble vascular endothelial growth factor receptor 1.

###### 

Comparative analysis of the expression level of C\'s C of the patients in PGN group and SGN group before and after treatment.

  Groups             Before patients were treated   In one cycle after patients were treated                  In three cycles after patients were treated                                                            After patients were discharged                                                                  F-value   P-value
  ------------------ ------------------------------ --------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------- --------- ---------
  SGN group (n=52)   2.42±0.42                      2.11±0.34^[a](#tfn1-etm-0-0-8824){ref-type="table-fn"}^   1.62±0.30^[a](#tfn1-etm-0-0-8824){ref-type="table-fn"},[b](#tfn2-etm-0-0-8824){ref-type="table-fn"}^   0.45±0.22^[a-c](#tfn1-etm-0-0-8824 tfn2-etm-0-0-8824 tfn3-etm-0-0-8824){ref-type="table-fn"}^   0.842     \<0.001
  PGN group (n=36)   2.43±0.45                      2.12±0.42^[a](#tfn1-etm-0-0-8824){ref-type="table-fn"}^   1.64±0.35^[a](#tfn1-etm-0-0-8824){ref-type="table-fn"},[b](#tfn2-etm-0-0-8824){ref-type="table-fn"}^   0.42±0.24^[a-c](#tfn1-etm-0-0-8824 tfn2-etm-0-0-8824 tfn3-etm-0-0-8824){ref-type="table-fn"}^   0.812     \<0.001
  t-test             0.107                          0.123                                                     0.287                                                                                                  0.606                                                                                                      
  P-value            0.915                          0.902                                                     0.775                                                                                                  0.546                                                                                                      

^a^P\<0.05, compared with before treatment in the same group

^b^P\<0.05 compared with one cycle of treatment in the same group;

^c^P\<0.05 compared with three cycles of treatment in the same group. C\'s C, serum cystatin C; PGN, primary glomerulonephritis; SGN, secondary glomerulonephritis.

###### 

Comparative analysis of the expression level of sVEGFR1 of the patients in PGN group and SGN group before and after treatment.

  Groups             Before the patients were treated   In one cycle after the patients were treated               In three cycles after the patients were treated                                                         After the patients were discharged                                                               F-value   P-value
  ------------------ ---------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ --------- ---------
  SGN group (n=52)   30.51±7.13                         26.43±6.46^[a](#tfn4-etm-0-0-8824){ref-type="table-fn"}^   21.42±5.25^[a](#tfn4-etm-0-0-8824){ref-type="table-fn"},[b](#tfn5-etm-0-0-8824){ref-type="table-fn"}^   17.34±5.13^[a-c](#tfn4-etm-0-0-8824 tfn5-etm-0-0-8824 tfn6-etm-0-0-8824){ref-type="table-fn"}^   0.409     \<0.001
  PGN group (n=36)   30.42±7.42                         26.32±6.42^[a](#tfn4-etm-0-0-8824){ref-type="table-fn"}^   21.53±5.63^[a](#tfn4-etm-0-0-8824){ref-type="table-fn"},[b](#tfn5-etm-0-0-8824){ref-type="table-fn"}^   17.45±5.26^[a-c](#tfn4-etm-0-0-8824 tfn5-etm-0-0-8824 tfn6-etm-0-0-8824){ref-type="table-fn"}^   0.387     \<0.001
  t-test             0.057                              0.079                                                      0.094                                                                                                   0.098                                                                                                       
  P-value            0.955                              0.937                                                      0.926                                                                                                   0.922                                                                                                       

^a^P\<0.05, compared with before treatment in the same group;

^b^P\<0.05 compared with a cycle of treatment in the same group;

^c^P\<0.05 compared with three cycles of treatment in the same group. sVEGFR1, soluble vascular endothelial growth factor receptor 1; PGN, primary glomerulonephritis; SGN, secondary glomerulonephritis.

###### 

Changes in renal function of the study group in different periods of treatment.

  Groups                   Before patients were treated   One cycle after patients were treated                        Three cycles after patients were treated                                                                  After patients were discharged                                                                     F-value   P-value
  ------------------------ ------------------------------ ------------------------------------------------------------ --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- --------- ---------
  Urea nitrogen (mmol/l)   14.34±1.23                     12.42±1.14^[a](#tfn7-etm-0-0-8824){ref-type="table-fn"}^     10.41±1.08^[a](#tfn7-etm-0-0-8824){ref-type="table-fn"},[b](#tfn8-etm-0-0-8824){ref-type="table-fn"}^     7.65±0.84^[a-c](#tfn7-etm-0-0-8824 tfn8-etm-0-0-8824 tfn9-etm-0-0-8824){ref-type="table-fn"}^      615.500   \<0.001
  Creatinine (umol/l)      293.43±32.32                   241.52±31.02^[a](#tfn7-etm-0-0-8824){ref-type="table-fn"}^   174.41±30.73^[a](#tfn7-etm-0-0-8824){ref-type="table-fn"},[b](#tfn8-etm-0-0-8824){ref-type="table-fn"}^   161.41±28.26^[a-c](#tfn7-etm-0-0-8824 tfn8-etm-0-0-8824 tfn9-etm-0-0-8824){ref-type="table-fn"}^   440.900   \<0.001

^a^P\<0.05, compared with before treatment in the same group;

^b^P\<0.05 compared with one cycle of treatment in the same group;

^c^P\<0.05 compared with three cycles of treatment in the same group.
